Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as a 30 mg tablet for oral use. It treats and helps prevent cerebral vasospasm after subarachnoid hemorrhage and may be used in cerebral ischemia. GNH USA supplies Nimotop as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimotop is a calcium channel blocker used in cerebrovascular conditions to improve outcomes. - Prevention of cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits. - Cerebral ischemia: enhances cerebral blood flow in patients with reduced perfusion. - Management of subarachnoid hemorrhage complications: supports neurological recovery by maintaining adequate cerebral circulation.

Nimotop may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of skin. - Hypotension: occasional drop in blood pressure. - Nausea: mild gastrointestinal upset. - Dizziness: sensation of light‑headedness. - Peripheral edema: swelling of lower limbs.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction requiring medical attention. - Myocardial infarction: rare cardiac event. - Arrhythmias: abnormal heart rhythms. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, Stevens‑Johnson syndrome, or anaphylaxis. - Thrombocytopenia: low platelet count.

Before initiating Nimotop, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal or hepatic impairment: adjust monitoring as needed. - Hypotension: observe blood pressure, especially with other antihypertensives. - Concomitant nitrates: avoid combined use due to additive vasodilatory effect. - Pregnancy and lactation: use only if benefit outweighs risk, as safety is not established. - Elderly patients: consider lower starting dose and monitor for dizziness. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Nimotop can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concomitant use with other potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nimodipine plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardia. - Diuretics: may potentiate hypotensive effect. - Anticoagulants: monitor for bleeding if hypotension occurs.